Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Citi
McKesson
Chinese Patent Office
Colorcon
Harvard Business School
Merck
McKinsey
QuintilesIMS
Accenture

Generated: August 19, 2017

DrugPatentWatch Database Preview

Verapamil hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for verapamil hydrochloride and what is the scope of verapamil hydrochloride freedom to operate?

Verapamil hydrochloride
is the generic ingredient in seven branded drugs marketed by Glenmark Generics, Mylan, Recro Gainesville, Luitpold, Gd Searle Llc, Actavis Elizabeth, Pliva, Sandoz, Watson Labs, Exela Pharma Scs Llc, Sun Pharm Inds Inc, Ivax Sub Teva Pharms, Marsam Pharms Llc, Hospira, Warner Chilcott, Abraxis Pharm, Intl Medication, Pfizer, Par Pharm, Cadila Pharms Ltd, Apotex Corp, Heritage Pharms Inc, Mutual Pharm, Mt Adams, Bedford, Sun Pharm Inds, Solopak, and Smith And Nephew, and is included in sixty-two NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Verapamil hydrochloride has eighteen patent family members in sixteen countries.

There are sixteen drug master file entries for verapamil hydrochloride. Thirty-eight suppliers are listed for this compound.

Summary for Generic Name: verapamil hydrochloride

Tradenames:7
Patents:1
Applicants:28
NDAs:62
Drug Master File Entries: see list16
Suppliers / Packagers: see list38
Bulk Api Vendors: see list71
Clinical Trials: see list2,344
Patent Applications: see list3,546
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:verapamil hydrochloride at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-001Feb 26, 1996DISCNNoNo► Subscribe► Subscribe ► Subscribe
Heritage Pharms Inc
VERAPAMIL HYDROCHLORIDE
verapamil hydrochloride
TABLET;ORAL071880-001Apr 5, 1988ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan
VERAPAMIL HYDROCHLORIDE
verapamil hydrochloride
TABLET;ORAL071483-002Feb 15, 1989ABRXNoNo► Subscribe► Subscribe► Subscribe
Watson Labs
VERAPAMIL HYDROCHLORIDE
verapamil hydrochloride
TABLET;ORAL070856-001Sep 24, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-001Nov 25, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: verapamil hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-002Feb 26, 1996► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-002Nov 25, 1998► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-002Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-002Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-001Feb 26, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: verapamil hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,534,089 Uniform drug delivery therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: verapamil hydrochloride

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)9737640► Subscribe
Germany69709101► Subscribe
Canada2586473► Subscribe
Argentina006087► Subscribe
European Patent Office0907358► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Accenture
Cerilliant
Citi
Colorcon
Chinese Patent Office
Medtronic
McKinsey
Johnson and Johnson
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot